دورية أكاديمية
أعرض في EDS

Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

التفاصيل البيبلوغرافية
العنوان: Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.
المؤلفون: Sattar N; British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. nsattar@clinmed.gla.ac.uk, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I
المصدر: Lancet (London, England) [Lancet] 2010 Feb 27; Vol. 375 (9716), pp. 735-42. Date of Electronic Publication: 2010 Feb 16.
نوع المنشور: Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
أسماء مطبوعة: Publication: 2004- : London : Elsevier
Original Publication: London : J. Onwhyn
مواضيع طبية MeSH: Anticholesteremic Agents/*adverse effects , Cardiovascular Diseases/*drug therapy , Diabetes Mellitus, Type 2/*chemically induced , Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects, Age Distribution ; Age Factors ; Aged ; Diabetes Mellitus, Type 2/epidemiology ; Female ; Humans ; Male ; Middle Aged ; Randomized Controlled Trials as Topic ; Risk Factors ; Treatment Outcome
مستخلص: Background: Trials of statin therapy have had conflicting findings on the risk of development of diabetes mellitus in patients given statins. We aimed to establish by a meta-analysis of published and unpublished data whether any relation exists between statin use and development of diabetes.
Methods: We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials from 1994 to 2009, for randomised controlled endpoint trials of statins. We included only trials with more than 1000 patients, with identical follow-up in both groups and duration of more than 1 year. We excluded trials of patients with organ transplants or who needed haemodialysis. We used the I(2) statistic to measure heterogeneity between trials and calculated risk estimates for incident diabetes with random-effect meta-analysis.
Findings: We identified 13 statin trials with 91 140 participants, of whom 4278 (2226 assigned statins and 2052 assigned control treatment) developed diabetes during a mean of 4 years. Statin therapy was associated with a 9% increased risk for incident diabetes (odds ratio [OR] 1.09; 95% CI 1.02-1.17), with little heterogeneity (I(2)=11%) between trials. Meta-regression showed that risk of development of diabetes with statins was highest in trials with older participants, but neither baseline body-mass index nor change in LDL-cholesterol concentrations accounted for residual variation in risk. Treatment of 255 (95% CI 150-852) patients with statins for 4 years resulted in one extra case of diabetes.
Interpretation: Statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events. Clinical practice in patients with moderate or high cardiovascular risk or existing cardiovascular disease should not change.
Funding: None.
(Copyright 2010 Elsevier Ltd. All rights reserved.)
التعليقات: Comment in: Lancet. 2010 Feb 27;375(9716):700-1. (PMID: 20167360)
Comment in: Evid Based Med. 2010 Jun;15(3):84-5. (PMID: 20522688)
Comment in: Ann Intern Med. 2010 Jun 15;152(12):JC6-7. (PMID: 20547901)
Comment in: Lancet. 2010 Jun 19;375(9732):2139-40; author reply 2141-2. (PMID: 20609943)
Comment in: Lancet. 2010 Jun 19;375(9732):2139; author reply 2141-2. (PMID: 20609944)
Comment in: Lancet. 2010 Jun 19;375(9732):2139; author reply 2141-2. (PMID: 20609945)
Comment in: Lancet. 2010 Jun 19;375(9732):2140; author reply 2141-2. (PMID: 20609946)
Comment in: Lancet. 2010 Jun 19;375(9732):2140-1; author reply 2141-2. (PMID: 20609947)
Comment in: Lancet. 2010 Jun 19;375(9732):2140; author reply 2141-2. (PMID: 20609948)
المشرفين على المادة: 0 (Anticholesteremic Agents)
0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
تواريخ الأحداث: Date Created: 20100220 Date Completed: 20100315 Latest Revision: 20230815
رمز التحديث: 20240829
DOI: 10.1016/S0140-6736(09)61965-6
PMID: 20167359
قاعدة البيانات: MEDLINE
الوصف
تدمد:1474-547X
DOI:10.1016/S0140-6736(09)61965-6